6DO6

NMR solution structure of wild type apo hFABP1 at 308 K

Summary for 6DO6

• Entry DOI: 10.2210/pdb6do6/pdb
• NMR Information: BMRB: 30477
• Descriptor: Fatty acid-binding protein, liver (1 entity in total)
• Functional Keywords: lipid binding protein
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 1
• Total formula weight: 15225.46

Authors

Scanlon, M.J.,Mohanty, B.,Doak, B.C.,Patil, R. (deposition date: 2018-06-09, release date: 2018-12-26, Last modification date: 2024-05-01)

Primary citation

Patil, R.,Mohanty, B.,Liu, B.,Chandrashekaran, I.R.,Headey, S.J.,Williams, M.L.,Clements, C.S.,Ilyichova, O.,Doak, B.C.,Genissel, P.,Weaver, R.J.,Vuillard, L.,Halls, M.L.,Porter, C.J.H.,Scanlon, M.J.
A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor alpha agonists.
J. Biol. Chem., 294:3720-3734, 2019

PubMed Abstract: Peroxisome proliferator-activated receptor α (PPARα) is a transcriptional regulator of lipid metabolism. GW7647 is a potent PPARα agonist that must reach the nucleus to activate this receptor. In cells expressing human fatty acid-binding protein 1 (FABP1), GW7647 treatment increases FABP1's nuclear localization and potentiates GW7647-mediated PPARα activation; GW7647 is less effective in cells that do not express FABP1. To elucidate the underlying mechanism, here we substituted residues in FABP1 known to dictate lipid signaling by other intracellular lipid-binding proteins. Substitutions of Lys-20 and Lys-31 to Ala in the FABP1 helical cap affected neither its nuclear localization nor PPARα activation. In contrast, Ala substitution of Lys-57, Glu-77, and Lys-96, located in the loops adjacent to the ligand-binding portal region, abolished both FABP1 nuclear localization and GW7647-induced PPARα activation but had little effect on GW7647-FABP1 binding affinity. Using solution NMR spectroscopy, we determined the WT FABP1 structure and analyzed the dynamics in the apo and GW7647-bound structures of both the WT and the K57A/E77A/K96A triple mutant. We found that GW7647 binding causes little change in the FABP1 backbone, but solvent exposes several residues in the loops around the portal region, including Lys-57, Glu-77, and Lys-96. These residues also become more solvent-exposed upon binding of FABP1 with the endogenous PPARα agonist oleic acid. Together with previous observations, our findings suggest that GW7647 binding stabilizes a FABP1 conformation that promotes its interaction with PPARα. We conclude that full PPARα agonist activity of GW7647 requires FABP1-dependent transport and nuclear localization processes.

PubMed: 30598509
DOI: 10.1074/jbc.RA118.006848

Experimental method

SOLUTION NMR